Currently, the only FDA-approved therapy for focal occlusive ischemia in the brain is the administration of the thrombolytic agent tissue plasminogen activator (tPA), which may have the risk of bleeding complications (Ohsawa et al., 2005). This evidence concerns the gene PLAT and ischemia.